Yondelis May Be New Mesothelioma Treatment Option, Researchers Say

New research suggests that Yondelis, a drug already approved to treat ovarian cancer, may also prove effective for treating the rare cancer mesothelioma, which is caused by exposure to asbestos and extremely difficult to treat. 

In a study published this month in the medical journal Molecular Cancer Therapeutics, Italian researchers indicate that Yondelis (trabectedin) was able to kill cells from six different mesothelioma cell lines.

Researchers from the University of Vienna say that it could one day potentially be a treatment for malignant pleural mesothelioma (MPM) as well.

|
|

The study involved the use of the drug on six malignant pleural mesothelioma cell lines, 13 primary cell cultures from surgical pleural mesothelioma specimens as two non-malignant pleural mesothelioma tissue samples. Researchers found a dose-dependent effect on all malignant pleural mesothelioma cell cultures. The drug also appeared to increase in effectiveness when used with some other mesothelioma treatments.

The study concludes that Yondelis “represents a promising new therapeutic option” for the treatment of malignant pleural mesothelioma.

Mesothelioma is only known to be caused by exposure to asbestos and breathing asbestos fibers. It is an especially lethal form of cancer, which is often at a very advanced stage when a diagnosis is made, resulting in a very short life-expectancy for individuals diagnosed with the cancer.

The disease is often the subject of asbestos lawsuits among individuals diagnosed with mesothelioma, involving allegations that manufacturers of various asbestos-containing products failed to take adequate safety measures or warn about the risk of cancer long after exposure to the substance.

More than 600,000 people throughout the United States having filed a cases against more than 6,000 defendants after being diagnosed with mesothelioma or other related injuries that were allegedly caused by inhaling asbestos fibers.

In addition to claims for workers exposed to asbestos in the course of her employment, in recent years there have been a growing number of secondary exposure mesothelioma cases have been brought on behalf of spouses, children and other family members alleging they developed the disease after breathing asbestos fibers brought home in the hair or on the clothing of individuals who worked directly with the material.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Lawsuits over Ozempic and Wegovy vision loss will be consolidated for pretrial proceedings in New Jersey, separate from claims involving gastrointestinal injuries.
Former Becton Dickinson safety officer Dr. Hooman Noorchashm warns that the company’s GalaFLEX mesh is being used off-label in breast reconstruction without FDA approval, as lawsuits investigate whether the manufacturer failed to warn about its potential risks.
A series of case management conferences have been scheduled for hair relaxer litigation throughout 2026, leading up to expected bellwether trials in 2027.